Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Kyunghee University Medical Center
The aims of this study is to evaluate the effects of platelet responsiveness to clopidogrel or cilostazol in CKD patients undergoing hemodialysis. The differences in platelet activation markers are also evaluated before and after clopidogrel or cilostazol administration. The investigators will perform a prospective, randomized study to compare the degree of platelet inhibition and platelet activation markers by adjunctive cilostazol (100 mg twice daily) compared to clopidogrel (75 or 150 mg/day) in CKD patients undergoing hemodialysis.
Age
20–80
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
CKD patients undergoing chronic hemodialysis and PCI for stable coronary artery disease
You may not be if
known allergies to aspirin, clopidogrel, or cilostazol thienopyridine use before enrollment
concomitant use of other anti-thrombotic drugs (oral anticoagulants and dipyridamole)
platelet count \<100 x 106/μL
hematocrit \< 25%
liver disease (bilirubin \> 2 mg/dl)
active bleeding or bleeding diathesis
gastrointestinal bleeding within the last 6 months
hemodynamic instability
acute coronary or cerebrovascular event within 3 months
malignancy
concomitant use of a cytochrome P450 inhibitor or a non-steroidal anti-inflammatory drug
recent treatment (\<30 days) with a glycoprotein IIb/IIIa antagonist.
